1. Home
  2. CINGW vs ZLAB Comparison

CINGW vs ZLAB Comparison

Compare CINGW & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • ZLAB
  • Stock Information
  • Founded
  • CINGW N/A
  • ZLAB 2013
  • Country
  • CINGW United States
  • ZLAB China
  • Employees
  • CINGW 13
  • ZLAB N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • ZLAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • CINGW Health Care
  • ZLAB Health Care
  • Exchange
  • CINGW Nasdaq
  • ZLAB Nasdaq
  • Market Cap
  • CINGW N/A
  • ZLAB N/A
  • IPO Year
  • CINGW 2021
  • ZLAB 2017
  • Fundamental
  • Price
  • CINGW $0.06
  • ZLAB $36.43
  • Analyst Decision
  • CINGW
  • ZLAB Buy
  • Analyst Count
  • CINGW 0
  • ZLAB 4
  • Target Price
  • CINGW N/A
  • ZLAB $47.37
  • AVG Volume (30 Days)
  • CINGW N/A
  • ZLAB 900.2K
  • Earning Date
  • CINGW N/A
  • ZLAB 05-07-2025
  • Dividend Yield
  • CINGW N/A
  • ZLAB N/A
  • EPS Growth
  • CINGW N/A
  • ZLAB N/A
  • EPS
  • CINGW N/A
  • ZLAB N/A
  • Revenue
  • CINGW N/A
  • ZLAB $398,988,000.00
  • Revenue This Year
  • CINGW N/A
  • ZLAB $45.57
  • Revenue Next Year
  • CINGW N/A
  • ZLAB $47.91
  • P/E Ratio
  • CINGW N/A
  • ZLAB N/A
  • Revenue Growth
  • CINGW N/A
  • ZLAB 49.59
  • 52 Week Low
  • CINGW N/A
  • ZLAB $13.48
  • 52 Week High
  • CINGW N/A
  • ZLAB $39.77
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • ZLAB 54.88
  • Support Level
  • CINGW N/A
  • ZLAB $34.59
  • Resistance Level
  • CINGW N/A
  • ZLAB $38.70
  • Average True Range (ATR)
  • CINGW 0.00
  • ZLAB 1.65
  • MACD
  • CINGW 0.00
  • ZLAB -0.26
  • Stochastic Oscillator
  • CINGW 0.00
  • ZLAB 48.14

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: